A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

Recruiting now · Phase 2

Conditions studied: Non-Small Cell Lung Cancer

In brief

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.

Key facts

Study ID
NCT07098338
Run by
AstraZeneca
People needed
278
Starts
2025-08-07
Expected to finish
2029-04-06
Last updated by the study team
2026-07-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.